Top

The European Journal of Health Economics

Published in:

Open Access 01-06-2019 | Crohn's Disease | Original Paper

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states

Authors: Fanni Rencz, Peep F. M. Stalmeier, Márta Péntek, Valentin Brodszky, Gábor Ruzsa, Lóránt Gönczi, Károly Palatka, László Herszényi, Eszter Schäfer, János Banai, Mariann Rutka, László Gulácsi, Peter L. Lakatos

Published in: The European Journal of Health Economics | Special Issue 1/2019

Abstract

Background

In patients with Crohn’s disease (CD), luminal disease activity paralleled by perianal fistulas may seriously impair health-related quality of life (HRQoL). Health utility values are not available from patients with CD that reflect the health loss associated with both luminal and perianal CD.

Objective

To generate utilities for luminal and concomitant perianal fistulising CD health states directly from patients and from members of the general public.

Methods

A cross-sectional survey was undertaken enrolling CD patients and a convenience sample of members of the general population. Respondents were asked to evaluate four common CD heath states [severe luminal disease (sCD), mild luminal disease (mCD), severe luminal disease with active perianal fistulas (sPFCD), and mild luminal disease with active perianal fistulas (mPFCD)] by 10-year time trade-off (TTO). In addition, patients assessed their current HRQoL by the TTO method.

Results

Responses of 206 patients (40.8% with perianal fistulas) and 221 members of the general population were analysed. Mean ± SD utilities among patients for sPFCD, sCD, mPFCD and mCD states were 0.69 ± 0.33, 0.73 ± 0.31, 0.80 ± 0.29 and 0.87 ± 0.26. Corresponding values in the general public were: 0.59 ± 0.31, 0.65 ± 0.29, 0.80 ± 0.26 and 0.88 ± 0.25. Patients with active perianal fistulas, previous non-resection surgeries, and higher pain intensity scores valued their current health as worse (p < 0.05).

Conclusions

TTO is a feasible method to assess HRQoL in patients with perianal fistulising disease, often not captured by health status questionnaires. Utilities from this study are intended to support the optimization of treatment-related decision making in patients with luminal disease paralleled by active perianal fistulas.

Available only for authorised users

Torres, J., Mehandru, S., Colombel, J.F., Peyrin-Biroulet, L.: Crohn’s disease. Lancet 389(10080), 1741–1755 (2017). https://doi.org/10.1016/s0140-6736(16)31711-1 CrossRefPubMed

Panes, J., Rimola, J.: Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat. Rev. Gastroenterol. Hepatol. 14(11), 652–664 (2017). https://doi.org/10.1038/nrgastro.2017.104 CrossRefPubMed

Mikocka-Walus, A., Knowles, S.R., Keefer, L., Graff, L.: Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm. Bowel Dis. 22(3), 752–762 (2016). https://doi.org/10.1097/mib.0000000000000620 CrossRefPubMed

Neuendorf, R., Harding, A., Stello, N., Hanes, D., Wahbeh, H.: Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J. Psychosom. Res. 87, 70–80 (2016). https://doi.org/10.1016/j.jpsychores.2016.06.001 CrossRefPubMed

Alrubaiy, L., Rikaby, I., Dodds, P., Hutchings, H.A., Williams, J.G.: Systematic review of health-related quality of life measures for inflammatory bowel disease. J. Crohns Colitis 9(3), 284–292 (2015). https://doi.org/10.1093/ecco-jcc/jjv002 CrossRefPubMed

Rencz, F., Lakatos, P.L., Gulacsi, L., Brodszky, V., Kurti, Z., Lovas, S., Banai, J., Herszenyi, L., Cserni, T., Molnar, T., Pentek, M., Palatka, K.: Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Qual. Life Res. 28(1), 141–152 (2019). https://doi.org/10.1007/s11136-018-2003-4 CrossRefPubMed

Vollebregt, P.F., van Bodegraven, A.A., Markus-de Kwaadsteniet, T.M.L., van der Horst, D., Felt-Bersma, R.J.F.: Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 47(9), 1253–1260 (2018). https://doi.org/10.1111/apt.14599 CrossRefPubMedPubMedCentral

Knowles, S.R., Graff, L.A., Wilding, H., Hewitt, C., Keefer, L., Mikocka-Walus, A.: Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm. Bowel Dis. 24(4), 742–751 (2018). https://doi.org/10.1093/ibd/izx100 CrossRefPubMed

Knowles, S.R., Keefer, L., Wilding, H., Hewitt, C., Graff, L.A., Mikocka-Walus, A.: Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm. Bowel Dis. 24(5), 966–976 (2018). https://doi.org/10.1093/ibd/izy015 CrossRefPubMed

10.

van der Have, M., van der Aalst, K.S., Kaptein, A.A., Leenders, M., Siersema, P.D., Oldenburg, B., Fidder, H.H.: Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J. Crohns Colitis 8(2), 93–106 (2014). https://doi.org/10.1016/j.crohns.2013.04.007 CrossRefPubMed

11.

Malinowski, K.P., Kawalec, P.: Health utility of patients with Crohn’s disease and ulcerative colitis: a systematic review and meta-analysis. Expert Rev. Pharmacoecon. Outcomes Res. 16(4), 441–453 (2016). https://doi.org/10.1080/14737167.2016.1190644 CrossRefPubMed

12.

Torrance, G.W.: Utility approach to measuring health-related quality of life. J. Chron. Dis. 40(6), 593–603 (1987)CrossRef

13.

Torrance, G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1–30 (1986)CrossRef

14.

Rencz, F., Pentek, M., Bortlik, M., Zagorowicz, E., Hlavaty, T., Sliwczynski, A., Diculescu, M.M., Kupcinskas, L., Gecse, K.B., Gulacsi, L., Lakatos, P.L.: Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J. Gastroenterol. 21(6), 1728–1737 (2015). https://doi.org/10.3748/wjg.v21.i6.1728 CrossRefPubMedPubMedCentral

15.

Pentek, M., Lakatos, P.L., Oorsprong, T., Gulacsi, L., Pavlova, M., Groot, W., Rencz, F., Brodszky, V., Baji, P., Crohn’s Disease Research, G: Access to biologicals in Crohn’s disease in ten European countries. World J. Gastroenterol. 23(34), 6294–6305 (2017). https://doi.org/10.3748/wjg.v23.i34.6294 CrossRefPubMedPubMedCentral

16.

Gulacsi, L., Pentek, M., Rencz, F., Brodszky, V., Baji, P., Vegh, Z., Gecse, K.B., Danese, S., Peyrin-Biroulet, L., Lakatos, P.L.: Biosimilars for the management of inflammatory bowel diseases: economic considerations. Curr. Med. Chem. 2019;26(2):259-269 https://doi.org/10.2174/0929867324666170406112304 CrossRefPubMed

17.

Rencz, F., Gulacsi, L., Pentek, M., Gecse, K.B., Dignass, A., Halfvarson, J., Gomollon, F., Baji, P., Peyrin-Biroulet, L., Lakatos, P.L., Brodszky, V.: Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev. Pharmacoecon. Outcomes Res. 17(6), 597–606 (2017). https://doi.org/10.1080/14737167.2017.1322509 CrossRefPubMed

18.

Arseneau, K.O., Cohn, S.M., Cominelli, F., Connors Jr., A.F.: Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 120(7), 1640–1656 (2001)CrossRef

19.

Gregor, J.C., McDonald, J.W., Klar, N., Wall, R., Atkinson, K., Lamba, B., Feagan, B.G.: An evaluation of utility measurement in Crohn’s disease. Inflamm. Bowel Dis. 3(4), 265–276 (1997)CrossRef

20.

Tillinger, W., Mittermaier, C., Lochs, H., Moser, G.: Health-related quality of life in patients with Crohn’s disease: influence of surgical operation–a prospective trial. Dig. Dis. Sci. 44(5), 932–938 (1999)CrossRef

21.

Mahadev, S., Young, J.M., Selby, W., Solomon, M.J.: Self-reported depressive symptoms and suicidal feelings in perianal Crohn’s disease. Colorect. Dis. 14(3), 331–335 (2012). https://doi.org/10.1111/j.1463-1318.2011.02613.x CrossRef

22.

Longworth, L., Fountain, D., Singh, J., Azzabi, I., Owen, G., Lundstam, U., Sebastian, S.: Elicitation of health-related utility in perianal fistula in Crohn’s disease. Patient (2018). https://doi.org/10.1007/s40271-018-0352-2. (Epub ahead of print) CrossRef

23.

Winship, D.H., Summers, R.W., Singleton, J.W., Best, W.R., Becktel, J.M., Lenk, L.F., Kern Jr., F.: National Cooperative Crohn’s Disease Study: study design and conduct of the study. Gastroenterology 77(4 Pt 2), 829–842 (1979)CrossRef

24.

Irvine, E.J.: Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J. Clin. Gastroenterol. 20(1), 27–32 (1995)CrossRef

25.

Losco, A., Vigano, C., Conte, D., Cesana, B.M., Basilisco, G.: Assessing the activity of perianal Crohn’s disease: comparison of clinical indices and computer-assisted anal ultrasound. Inflamm. Bowel Dis. 15(5), 742–749 (2009). https://doi.org/10.1002/ibd.20826 CrossRefPubMed

26.

Schunemann, H.J., Stahl, E., Austin, P., Akl, E., Armstrong, D., Guyatt, G.H.: A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease. Med. Decis. Making 24(1), 53–60 (2004). https://doi.org/10.1177/0272989x03261566 CrossRefPubMed

27.

Arnesen, T., Trommald, M.: Are QALYs based on time trade-off comparable?—a systematic review of TTO methodologies. Health Econ. 14(1), 39–53 (2005). https://doi.org/10.1002/hec.895 CrossRefPubMed

28.

Oppe, M., Devlin, N.J., van Hout, B., Krabbe, P.F., de Charro, F.: A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health 17(4), 445–453 (2014). https://doi.org/10.1016/j.jval.2014.04.002 CrossRefPubMed

29.

Poor, A.K., Brodszky, V., Pentek, M., Gulacsi, L., Ruzsa, G., Hidvegi, B., Hollo, P., Karpati, S., Sardy, M., Rencz, F.: Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch. Dermatol. Res. 310(1), 47–55 (2018). https://doi.org/10.1007/s00403-017-1794-4 CrossRefPubMed

30.

Rencz, F., Baji, P., Gulacsi, L., Karpati, S., Pentek, M., Poor, A.K., Brodszky, V.: Discrepancies between the Dermatology Life Quality Index and utility scores. Qual. Life Res. 25(7), 1687–1696 (2016). https://doi.org/10.1007/s11136-015-1208-z CrossRefPubMed

31.

Rencz, F., Brodszky, V., Stalmeier, P.F., Tamasi, B., Karpati, S., Pentek, M., Baji, P., Mitev, A.Z., Gulacsi, L.: Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. Br. J. Dermatol. 175(3), 593–599 (2016). https://doi.org/10.1111/bjd.14647 CrossRefPubMed

32.

Rencz, F., Pentek, M., Stalmeier, P.F.M., Brodszky, V., Ruzsa, G., Gradvohl, E., Baji, P., Gulacsi, L.: Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain 158(11), 2259–2267 (2017). https://doi.org/10.1097/j.pain.0000000000001028 CrossRefPubMed

33.

Hungarian Central Statistical Office, Microcensus 2016. ISBN 978-963-235-494-1ö. http://www.ksh.hu/docs/eng/xftp/idoszaki/microcensus2016/microcensus_2016_3.pdf. Accessed 24 Feb 2019

34.

Casellas, F., Vivancos, J.L., Sampedro, M., Malagelada, J.R.: Relevance of the phenotypic characteristics of Crohn’s disease in patient perception of health-related quality of life. Am. J. Gastroenterol. 100(12), 2737–2742 (2005). https://doi.org/10.1111/j.1572-0241.2005.00360.x CrossRefPubMed

35.

Baji, P., Gulácsi, L., Brodszky, V., Végh, Z., Danese, S., Irving, P.M., Peyrin-Biroulet, L., Schreiber, S., Rencz, F., Péntek, M.: Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United Eur. Gastroenterol. J. 6(2), 310–321 (2018). https://doi.org/10.1177/2050640617708952 CrossRef

36.

Clark, W., Raftery, J., Song, F., Barton, P., Cummins, C., Fry-Smith, A., Burls, A.: Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol. Assess. 7(3), 1–67 (2003)CrossRef

37.

Lindsay, J., Punekar, Y.S., Morris, J., Chung-Faye, G.: Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease–modelling outcomes in active luminal and fistulizing disease in adults. Aliment. Pharmacol. Ther. 28(1), 76–87 (2008). https://doi.org/10.1111/j.1365-2036.2008.03709.x CrossRefPubMed

38.

Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies. https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf (2006). Accessed 20 Feb 2019

39.

National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. https://www.nice.org.uk/guidance/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (2013). Accessed 20 Feb 2019

40.

Nederland, Zorginstituut: Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland, Diemen (2016)

41.

EUnetHTA Methods for health economic evaluations—a guideline based on current practices in Europe. https://www.eunethta.eu/wp-content/uploads/2018/03/Methods_for_health_economic_evaluations.pdf (2015). Accessed 11 Dec 2018

42.

Boncz, I., Sebestyen, A.: Financial deficits in the health services of the UK and Hungary. Lancet 368(9539), 917–918 (2006). https://doi.org/10.1016/s0140-6736(06)69369-0 CrossRefPubMed

43.

Versteegh, M.M., Brouwer, W.B.F.: Patient and general public preferences for health states: a call to reconsider current guidelines. Soc. Sci. Med. 1982(165), 66–74 (2016). https://doi.org/10.1016/j.socscimed.2016.07.043 CrossRef

44.

Mott, D.J.: Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? Patient 11(3), 249–252 (2018). https://doi.org/10.1007/s40271-018-0305-9 CrossRefPubMed

45.

Wale, J., Scott, A.M., Hofmann, B., Garner, S., Low, E., Sansom, L.: Why patients should be involved in health technology assessment. Int. J. Technol. Assess. Health Care 33(1), 1–4 (2017). https://doi.org/10.1017/s0266462317000241 CrossRefPubMed

46.

Muhlbacher, A.C.: Patient-centric HTA: different strokes for different folks. Expert Rev. Pharmacoecon. Outcomes Res. 15(4), 591–597 (2015). https://doi.org/10.1586/14737167.2015.1038245 CrossRefPubMed

47.

Sahnan, K., Tozer, P.J., Adegbola, S.O., Lee, M.J., Heywood, N., McNair, A.G.K., Hind, D., Yassin, N., Lobo, A.J., Brown, S.R., Sebastian, S., Phillips, R.K.S., Lung, P.F.C., Faiz, O.D., Crook, K., Blackwell, S., Verjee, A., Hart, A.L., Fearnhead, N.S.: Developing a core outcome set for fistulising perianal Crohn’s disease. Gut 68(2), 226–238 (2019). https://doi.org/10.1136/gutjnl-2017-315503 CrossRefPubMed

48.

Gecse, K.B., Sebastian, S., Hertogh, G., Yassin, N.A., Kotze, P.G., Reinisch, W., Spinelli, A., Koutroubakis, I.E., Katsanos, K.H., Hart, A., van den Brink, G.R., Rogler, G., Bemelman, W.A.: Results of the fifth scientific workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn’s disease-the unmet needs. J Crohns Colitis 10(7), 758–765 (2016). https://doi.org/10.1093/ecco-jcc/jjw039 CrossRefPubMed

49.

Lichtenstein, G.R., Loftus, E.V., Isaacs, K.L., Regueiro, M.D., Gerson, L.B., Sands, B.E.: ACG clinical guideline: management of Crohn’s disease in adults. Am. J. Gastroenterol. 113(4), 481–517 (2018). https://doi.org/10.1038/ajg.2018.27 CrossRefPubMed

50.

Adegbola, S., Dibley, L., Sahnan, K., Tozer, P., Yassin, N., Wade, T., Verjee, A., Sawyer, R., Mannick, S., Lung, P.: N001 Developing a quality of life score for Crohn’s anal fistula (CAF-QoL). J. Crohn’s Colitis 12(1), S568 (2018)

Title: Patient and general population values for luminal and perianal fistulising Crohn’s disease health states
Authors: Fanni Rencz
Peep F. M. Stalmeier
Márta Péntek
Valentin Brodszky
Gábor Ruzsa
Lóránt Gönczi
Károly Palatka
László Herszényi
Eszter Schäfer
János Banai
Mariann Rutka
László Gulácsi
Peter L. Lakatos
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keyword: Crohn's Disease
Published in: The European Journal of Health Economics / Issue Special Issue 1/2019
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-019-01065-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states

Abstract

Background

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 1/2019

Patient-reported outcomes: opportunities and challenges in Central Europe

Subjective well-being in patients with pemphigus: a path analysis

Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies

Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary

Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary

Psychometric properties of the Hungarian version of the eHealth Literacy Scale